Another predictive biomarker for HNSCC therapy, PD-L1 cumulative positivity score, has been used in the clinic to predict ICI responsiveness but only achieves a receiver operating characteristic of 0.62 in recurrent/metastatic HNSCC (16). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.